Total Payments
$1.4M
2024 Payments
$97,307
Companies
48
Transactions
2,412
Medicare Patients
3,273
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$921,429 (67.1%)
Consulting$312,459 (22.8%)
Travel$74,025 (5.4%)
Food & Beverage$48,688 (3.5%)
Research$16,084 (1.2%)
Education$408.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $859,678 | 449 | 62.6% |
| Consulting Fee | $312,459 | 141 | 22.8% |
| Travel and Lodging | $74,025 | 314 | 5.4% |
| Honoraria | $61,663 | 34 | 4.5% |
| Food and Beverage | $48,688 | 1,463 | 3.5% |
| Unspecified | $16,084 | 5 | 1.2% |
| Education | $408.50 | 4 | 0.0% |
| Grant | $87.90 | 2 | 0.0% |
Payments by Type
General
$1.4M
2,407 transactions
Research
$16,084
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $299,464 | 391 | $0 (2024) |
| ABBVIE INC. | $240,479 | 370 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $218,536 | 256 | $0 (2024) |
| Amgen Inc. | $204,883 | 311 | $0 (2024) |
| Lundbeck LLC | $66,985 | 113 | $0 (2024) |
| Allergan, Inc. | $60,318 | 108 | $0 (2022) |
| Biohaven Pharmaceuticals, Inc. | $43,956 | 56 | $0 (2021) |
| Supernus Pharmaceuticals, Inc. | $33,570 | 122 | $0 (2022) |
| IMPEL PHARMACEUTICALS INC. | $32,319 | 51 | $0 (2023) |
| Depomed, Inc. | $20,939 | 28 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $97,307 | 198 | ABBVIE INC. ($50,367) |
| 2023 | $153,421 | 275 | AbbVie Inc. ($100,000) |
| 2022 | $137,294 | 305 | ABBVIE INC. ($50,777) |
| 2021 | $181,007 | 309 | AbbVie Inc. ($39,335) |
| 2020 | $233,019 | 303 | Lilly USA, LLC ($66,566) |
| 2019 | $220,435 | 411 | Lilly USA, LLC ($73,723) |
| 2018 | $208,765 | 384 | Amgen Inc. ($66,303) |
| 2017 | $141,845 | 227 | Lilly USA, LLC ($53,570) |
All Payment Transactions
2,412 individual payment records from CMS Open Payments — Page 1 of 97
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | QULIPTA (Drug) | Consulting Fee | Cash or cash equivalent | $8,125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/20/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | Lundbeck LLC | VYEPTI (Biological) | Honoraria | Cash or cash equivalent | $3,390.00 | General |
| Category: NEUROLOGY | ||||||
| 12/17/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $28.09 | General |
| Category: NEUROLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2024 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $31.14 | General |
| Category: Neuroscience | ||||||
| 12/11/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $3.52 | General |
| Category: PAIN | ||||||
| 12/09/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Neuropsychiatry | ||||||
| 12/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: PAIN | ||||||
| 12/06/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $118.57 | General |
| Category: NEUROLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | QULIPTA (Drug) | Travel and Lodging | In-kind items and services | $743.76 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | ABBVIE INC. | QULIPTA (Drug) | Travel and Lodging | In-kind items and services | $407.96 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | ABBVIE INC. | QULIPTA (Drug) | Travel and Lodging | In-kind items and services | $115.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $31.33 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | ABBVIE INC. | QULIPTA (Drug) | Travel and Lodging | In-kind items and services | $20.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: NEUROLOGY | ||||||
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Central Nervous System | ||||||
| 12/03/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $31.60 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $2.89 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/02/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $28.44 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $4.46 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/20/2024 | Axsome Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,375.00 | General |
| 11/20/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $30.85 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: PAIN | ||||||
| 11/15/2024 | Eli Lilly and Company | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $68.71 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RANDOMIZED CONTROLLED TRIAL OF LASMIDITAN OVER FOUR MIGRAINE ATTACKS | Eli Lilly and Company | $13,468 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,616 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,032 | 20,941 | $1.3M | $334,118 |
| 2022 | 14 | 794 | 12,660 | $969,144 | $237,909 |
| 2021 | 15 | 773 | 7,840 | $926,300 | $227,062 |
| 2020 | 14 | 674 | 9,462 | $813,850 | $201,326 |
Total Patients
3,273
Total Services
50,903
Medicare Billing
$1.0M
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 100 | 1,239 | $495,600 | $115,773 | 23.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 42 | 18,072 | $252,966 | $88,909 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 358 | 772 | $231,600 | $72,111 | 31.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 96 | 137 | $95,900 | $17,492 | 18.2% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 40 | 82 | $94,300 | $10,941 | 11.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 59 | 59 | $29,500 | $10,361 | 35.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 64 | 91 | $36,400 | $8,338 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 73 | $14,600 | $4,661 | 31.9% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 12 | 13 | $3,900 | $2,053 | 52.6% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 90 | 105 | $5,250 | $1,275 | 24.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 41 | 110 | $8,250 | $1,221 | 14.8% |
| J1230 | Injection, methadone hcl, up to 10 mg | Office | 2023 | 16 | 37 | $1,850 | $467.25 | 25.3% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 24 | 44 | $1,100 | $388.44 | 35.3% |
| J2550 | Injection, promethazine hcl, up to 50 mg | Office | 2023 | 21 | 45 | $1,125 | $107.82 | 9.6% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 13 | 62 | $775.00 | $21.54 | 2.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 71 | 995 | $398,000 | $79,539 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 299 | 694 | $208,200 | $63,582 | 30.5% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 22 | 10,296 | $144,144 | $50,311 | 34.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 68 | 106 | $74,200 | $15,979 | 21.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 65 | 107 | $42,800 | $8,405 | 19.6% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 21 | 51 | $58,650 | $6,834 | 11.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 27 | 27 | $13,500 | $4,897 | 36.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 35 | 47 | $9,400 | $3,531 | 37.6% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 11 | 11 | $3,300 | $1,634 | 49.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 38 | 108 | $8,100 | $1,204 | 14.9% |
About Dr. Merle Diamond, MD
Dr. Merle Diamond, MD is a Internal Medicine healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1780676668.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Merle Diamond, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $97,307 received in 2024. These payments were reported across 2,412 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($859,678).
As a Medicare-enrolled provider, Diamond has provided services to 3,273 Medicare beneficiaries, totaling 50,903 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Chicago, IL
- Active Since 08/17/2005
- Last Updated 10/31/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1780676668
Products in Payments
- Aimovig (Biological) $178,763
- UBRELVY (Drug) $124,670
- QULIPTA (Drug) $123,293
- AJOVY (Biological) $104,925
- EMGALITY (Drug) $93,805
- AJOVY (Drug) $77,764
- VYEPTI (Biological) $62,291
- NURTEC ODT (Drug) $57,316
- REYVOW (Drug) $39,900
- TROKENDI XR (Drug) $33,554
- Trudhesa (Drug) $32,319
- Cambia (Drug) $31,980
- BOTOX (Biological) $26,160
- TEV-48125 (Biological) $18,963
- Zembrace (Drug) $15,454
- MIGRANAL (Drug) $15,245
- ONZETRA Xsail (Drug) $11,888
- ELYXYB - CELECOXIB (Drug) $6,820
- ELYXYB - celecoxib (Drug) $5,037
- TOSYMRA SUMATRIPTAN NASAL SPRAY (Drug) $4,870
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chicago
Dr. Myles Wolf, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Elizabeth Kiracofe, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Robert Kushner, Md, MD
Internal Medicine — Payments: $549,886
Internal Medicine $549,886
Dr. Adam Stein, M.d, M.D
Internal Medicine — Payments: $503,325
Internal Medicine $503,325
Devalingam Mahalingam, M.d, M.D
Internal Medicine — Payments: $501,247
Internal Medicine $501,247
Dr. Romeo Ursua, M.d, M.D
Internal Medicine — Payments: $410,468
Internal Medicine $410,468